Baricitinib, an oral highly selective JAK1 and JAK2 inhibitor has also been studied in patients with moderate-to-severe psoriasis in Phase II trials and has shown better efficacy as compared to placebo at doses 8 mg and 10 mg (19). Here, JAK1 is linked to psoriasis.